Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
18.29
+0.87 (4.99%)
Jan 2, 2025, 1:04 PM EST - Market open
Travere Therapeutics Employees
Travere Therapeutics had 380 employees as of December 31, 2023. The number of employees decreased by 82 or -17.75% compared to the previous year.
Employees
380
Change (1Y)
-82
Growth (1Y)
-17.75%
Revenue / Employee
$535,387
Profits / Employee
-$924,879
Market Cap
1.59B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
TVTX News
- 14 days ago - Travere Therapeutics: Cautiously Bullish Based On Improving Revenue - Seeking Alpha
- 15 days ago - Homocystinuria Therapeutics Market Research 2024: Insights About 3+ Companies and 3+ Pipeline Drugs Featuring Travere Therapeutics and Syntis Bio - GlobeNewsWire
- 5 weeks ago - Travere Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Travere Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 7 weeks ago - Travere Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Travere Therapeutics, Inc. (TVTX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024 - GlobeNewsWire